Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$519K Sell
1,434
-38
-3% -$13K 0.05% 138
2026
Q1
$518K Sell
1,472
-64
-4% -$22.8K 0.05% 135
2025
Q4
$503K Sell
1,536
-94
-6% -$29.8K 0.06% 129
2025
Q3
$460K Buy
1,630
+12
+0.7% +$3.48K 0.05% 134
2025
Q2
$452K Buy
1,618
+100
+7% +$28.3K 0.06% 129
2025
Q1
$473K Sell
1,518
-98
-6% -$28.9K 0.07% 108
2024
Q4
$419K Buy
1,616
+22
+1% +$6.53K 0.07% 117
2024
Q3
$514K Sell
1,594
-28
-2% -$9.16K 0.08% 107
2024
Q2
$507K Buy
1,622
+142
+10% +$41.7K 0.09% 102
2024
Q1
$421K Sell
1,480
-58
-4% -$17K 0.09% 103
2023
Q4
$443K Buy
+1,538
New +$419K 0.1% 98

Other funds holding AMGN

Legacy Edge Advisors's AMGN Position: Q2 2026 in Review

Legacy Edge Advisors reduced its Amgen (AMGN) stake by 2.6% in Q2 2026, selling an estimated $13K and leaving 1,434 shares worth $519K. The position accounts for 0.05% of the portfolio, ranked #138.

Legacy Edge Advisors first reported a position in AMGN in Q4 2023 and has held it in 11 quarters since. 3,163 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Legacy Edge Advisors held 1,434 shares of Amgen worth $519K as of Q2 2026.
  • Legacy Edge Advisors sold 38 Amgen shares in Q2 2026, an estimated $13K.
  • Amgen made up 0.05% of Legacy Edge Advisors's portfolio in Q2 2026, its #138 holding.
  • Legacy Edge Advisors first reported a position in Amgen in Q4 2023 and has held it in 11 quarters since.
  • 3,163 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Legacy Edge Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.